Instadose Selling General Administrative from 2010 to 2024
| INSD Stock | USD 0 0.00 0.00% |
Selling General Administrative | First Reported 2010-12-31 | Previous Quarter 531.3 K | Current Value 557.9 K | Quarterly Volatility 228.4 K |
Check Instadose Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Instadose Pharma's main balance sheet or income statement drivers, such as Interest Expense of 0.0, Selling General Administrative of 557.9 K or Total Revenue of 0.0, as well as many indicators such as Price To Sales Ratio of 1.6 K, Days Sales Outstanding of 0.0 or Free Cash Flow Yield of 0.0. Instadose financial statements analysis is a perfect complement when working with Instadose Pharma Valuation or Volatility modules.
Instadose | Selling General Administrative |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Instadose Pharma Corp is a strong investment it is important to analyze Instadose Pharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Instadose Pharma's future performance. For an informed investment choice regarding Instadose Stock, refer to the following important reports:Check out the analysis of Instadose Pharma Correlation against competitors. You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Instadose Pharma. If investors know Instadose will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Instadose Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.01) | Return On Assets (694.06) |
The market value of Instadose Pharma Corp is measured differently than its book value, which is the value of Instadose that is recorded on the company's balance sheet. Investors also form their own opinion of Instadose Pharma's value that differs from its market value or its book value, called intrinsic value, which is Instadose Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Instadose Pharma's market value can be influenced by many factors that don't directly affect Instadose Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Instadose Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Instadose Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Instadose Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.